AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27631958 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face ECLA
Number of subjects: 257
Study 27631958 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone ECLA
Number of subjects: 257
Study 27631958 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 257
Study 24720376 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg bid for 8 weeks
Number of subjects: 116
Study 24720376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 22848894 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implant-supported prosthesis (test group)
Number of subjects: 79
Study 22848894 — intervention group
Group type: COMPARATOR
Intervention: Conventional denture (control group)
Number of subjects: 79
Study 20835552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane + 0.1 mg/kg vecuronium
Number of subjects: 40
Study 20835552 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 40
Study 18192875 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin or its analogues
Number of subjects: 8
Study 15977096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2 % (Group R)
Number of subjects: 53
Study 15977096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2 % plus 1 mg/kg tramadol HCl (Group RT)
Number of subjects: 53
Study 15977096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2 % plus 0.1 mg/kg morphine HCl (Group RM)
Number of subjects: 53
Study 14657745 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 119
Study 14657745 — intervention group
Group type: COMPARATOR
Intervention: Anterior lumbar interbody fusion (ALIF)
Number of subjects: 119
Study 10480700 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisomy 18 cases (T18)
Number of subjects: 118
Study 10480700 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age >35 years (T18 cases)
Number of subjects: 118
Study 10480700 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age >30 years (T18 cases)
Number of subjects: 118
Study 10480700 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal healthy newborns)
Number of subjects: 118
Study 8944560 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholera toxin (15 micrograms)
Number of subjects: 7
Study 8944560 — intervention group
Group type: COMPARATOR
Intervention: Control (no cholera toxin)
Number of subjects: 7
Study 2066075 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (0.5 gm every 8 hr for 14 days)
Number of subjects: 44
Study 2066075 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (1 gm every 6 hr for 14 days)
Number of subjects: 44
Study 2066075 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 44
Study 2066075 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 44
Study 6230897 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine
Number of subjects: 119
Study 6230897 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 119
Study 6230897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 31093952 — intervention group
Group type: EXPERIMENTAL
Intervention: TNHH 0.2–1.8 mg/kg
Number of subjects: 68
Study 31093952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 30033422 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted nursing interventions combined with ear acupoint bean pressing treatment
Number of subjects: 158
Study 30033422 — intervention group
Group type: COMPARATOR
Intervention: Hepatology nursing, liver protecting and transaminase lowering medicine, and ear acupoint bean pressing treatment
Number of subjects: 158
Study 26399225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored behavioural medicine treatment (EXT)
Number of subjects: 32
Study 26399225 — intervention group
Group type: COMPARATOR
Intervention: Exercise-based treatment (CT)
Number of subjects: 32
Study 25449153 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-derived anti-nociceptive spray
Number of subjects: 60
Study 25449153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22157987 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid
Number of subjects: 181
Study 22157987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 19283736 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox (50% nitrous oxide and 50% oxygen)
Number of subjects: 131
Study 19283736 — intervention group
Group type: COMPARATOR
Intervention: midazolam-fentanyl
Number of subjects: 131
Study 17213237 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min locomotor training and 25 min physiotherapy (Group A)
Number of subjects: 155
Study 17213237 — intervention group
Group type: COMPARATOR
Intervention: 45 min physiotherapy every weekday for four weeks (Group B)
Number of subjects: 155
Study 16408140 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir 1,000 mg b.i.d. for genital herpes
Number of subjects: 0
Study 16408140 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir 1,500 mg single dose for labial herpes
Number of subjects: 0
Study 11821099 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg)
Number of subjects: 8
Study 11821099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9658616 — intervention group
Group type: EXPERIMENTAL
Intervention: GenHevac B vaccine (3 standard injections at one month interval)
Number of subjects: 46
Study 9658616 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-Interferon (5 MU thrice weekly subcutaneously for 4 months)
Number of subjects: 46
Study 9658616 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-Interferon and Vidarabine (12 of 22 patients)
Number of subjects: 46
Study 9658616 — intervention group
Group type: COMPARATOR
Intervention: preS2/S vaccine
Number of subjects: 46
Study 9658616 — intervention group
Group type: COMPARATOR
Intervention: S vaccine
Number of subjects: 46
Study 9658616 — intervention group
Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 46
Study 9658616 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine therapy
Number of subjects: 46
Study 8589319 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at a dose of 0.125 IU/kg per week for the first 4 weeks and 0.25 IU/kg per week thereafter
Number of subjects: 12
Study 8589319 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) therapy
Number of subjects: 12
Study 8589319 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 12
Study 2549780 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-polysaccharide fiber (SPF)
Number of subjects: 9
Study 2549780 — intervention group
Group type: COMPARATOR
Intervention: No soy-polysaccharide fiber (without SPF)
Number of subjects: 9
Study 185504 — intervention group
Group type: EXPERIMENTAL
Intervention: Etiroxate (40 mg daily) for 12 weeks
Number of subjects: 183
Study 185504 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 183
Study 31274072 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator group
Number of subjects: 25
Study 31274072 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 31321887 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate assisted partner services (aPS)
Number of subjects: 1119
Study 31321887 — intervention group
Group type: COMPARATOR
Intervention: Delayed assisted partner services (aPS)
Number of subjects: 1119
Study 27126371 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive soft tissue was debrided before implant placement (Group A)
Number of subjects: 60
Study 27126371 — intervention group
Group type: COMPARATOR
Intervention: Reactive soft tissue was left in the apical lesion (Group B)
Number of subjects: 60
Study 26117072 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (266 mg mixed with 75 mg 0.25% bupivacaine)
Number of subjects: 111
Study 26117072 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (150 mg 0.25%)
Number of subjects: 111
Study 23944203 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of beta-lactam antibiotics
Number of subjects: 420
Study 23944203 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus administration of beta-lactam antibiotics
Number of subjects: 420
Study 21736815 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity viscous fibre blend (VFB)
Number of subjects: 23
Study 21736815 — intervention group
Group type: COMPARATOR
Intervention: Medium-viscosity psyllium (PSY)
Number of subjects: 23
Study 21736815 — intervention group
Group type: COMPARATOR
Intervention: Low-viscosity wheat bran (WB)
Number of subjects: 23
Study 19579737 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate umbilical cord clamping (Group A)
Number of subjects: 200
Study 19579737 — intervention group
Group type: COMPARATOR
Intervention: Delayed umbilical cord clamping (Group B)
Number of subjects: 200
Study 17166396 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and usual diabetes care (EX)
Number of subjects: 30
Study 17166396 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetes care only (CON)
Number of subjects: 30
Study 12969102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (20 micro g) plus plain bupivacaine (10 mg)
Number of subjects: 60
Study 12969102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (50 micro g) plus plain bupivacaine (10 mg)
Number of subjects: 60
Study 12969102 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine (10 mg) with saline (control)
Number of subjects: 60
Study 10636148 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mIU IFNbeta‐1b
Number of subjects: 0
Study 10636148 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mIU IFNbeta‐1b
Number of subjects: 0
Study 10636148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9387742 — intervention group
Group type: EXPERIMENTAL
Intervention: Radix Salviae Miltiorrhizae (RSM) treatment group
Number of subjects: 30
Study 9387742 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 1390605 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium-rich yeast (160 micrograms Cr/d)
Number of subjects: 26
Study 1390605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3885424 — intervention group
Group type: EXPERIMENTAL
Intervention: isoxicam 200 mg once daily
Number of subjects: 30
Study 3885424 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 250 mg 3 times daily
Number of subjects: 30
Study 31456982 — intervention group
Group type: EXPERIMENTAL
Intervention: Husband participation with 2 training sessions and telephone counseling
Number of subjects: 66
Study 31456982 — intervention group
Group type: COMPARATOR
Intervention: Routine pregnancy care (Control)
Number of subjects: 66
Study 29972757 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen (300 mg weekly subcutaneous injections)
Number of subjects: 172
Study 29972757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 26497268 — intervention group
Group type: EXPERIMENTAL
Intervention: Win feedback preceded by wins at Outcomet-1
Number of subjects: 0
Study 26497268 — intervention group
Group type: COMPARATOR
Intervention: Win feedback preceded by losses at Outcomet-1
Number of subjects: 0
Study 26497268 — intervention group
Group type: COMPARATOR
Intervention: Loss feedback
Number of subjects: 0
Study 26497268 — intervention group
Group type: COMPARATOR
Intervention: Outcomet-2
Number of subjects: 0
Study 24488080 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (700 IU/day) and Calcium (500 mg/day)
Number of subjects: 279
Study 24488080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 22747608 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week dance program with 2, 90-minute dance classes per week
Number of subjects: 40
Study 22747608 — intervention group
Group type: COMPARATOR
Intervention: Control group with incentives for data collection
Number of subjects: 40
Study 22747608 — intervention group
Group type: COMPARATOR
Intervention: Control group with incentives and a delayed dance workshop
Number of subjects: 40
Study 21223651 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine mask combined with skin care (treatment group)
Number of subjects: 41
Study 21223651 — intervention group
Group type: COMPARATOR
Intervention: Common commercial beauty mask (control group)
Number of subjects: 41
Study 17433791 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 114
Study 17433791 — intervention group
Group type: COMPARATOR
Intervention: Equal contact exercise-placebo intervention
Number of subjects: 114
Study 17433791 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 114
Study 16261200 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b nasal spray (9 x 10(5) IU, twice per day for 5 days)
Number of subjects: 14391
Study 16261200 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b nasal spray
Number of subjects: 14391
Study 12137101 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 short breaks spaced hourly during cruise
Number of subjects: 28
Study 12137101 — intervention group
Group type: COMPARATOR
Intervention: 1 break in the middle of cruise (Control)
Number of subjects: 28
Study 9708636 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (FA; 500 mg/mq in 2‐hour intravenous infusion) and 5‐fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA) without hydroxyurea (HU) (arm A)
Number of subjects: 182
Study 9708636 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (FA; 500 mg/mq in 2‐hour intravenous infusion) and 5‐fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA) with hydroxyurea (35 mg/kg per day) (arm B)
Number of subjects: 182
Study 9708636 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both arms (A and B)
Number of subjects: 182
Study 7619975 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2-65% O2 inhalation during early-follicular phase
Number of subjects: 17
Study 7619975 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2-65% O2 inhalation during midluteal phase
Number of subjects: 17
Study 7619975 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CO2 inhalation)
Number of subjects: 17
Study 2244643 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 59
Study 2244643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 59
Study 2244643 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 59
Study 2244643 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study 485645 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate, 50 mg/day for 100 days
Number of subjects: 105
Study 485645 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate, 50 mg/day
Number of subjects: 105
Study 485645 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene therapy
Number of subjects: 105
Study 31718657 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal carotenoids measured by resonance Raman spectroscopy (RRS)
Number of subjects: 157
Study 31718657 — intervention group
Group type: COMPARATOR
Intervention: Self-reported fruit and vegetable intake (FVI) measures
Number of subjects: 157
Study 27310238 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 2140
Study 27310238 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 2140
Study 26796455 — intervention group
Group type: EXPERIMENTAL
Intervention: 180-degree laser photolysis (LP) treatment
Number of subjects: 28
Study 26796455 — intervention group
Group type: EXPERIMENTAL
Intervention: 360-degree laser photolysis (LP) treatment
Number of subjects: 28
Study 26796455 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated eyes)
Number of subjects: 28
Study 23242584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 912
Study 23242584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination score of positive pathway markers (p‐Akt, p‐mTOR, p‐ER)
Number of subjects: 912
Study 23242584 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear p‐Akt‐s473 and p‐ER at ‐s167 and/or ‐s305
Number of subjects: 912
Study 23242584 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (Control)
Number of subjects: 912
Study 21762157 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% w/w o-cymen-5-ol/ 0.6% w/w zinc chloride/ sodium fluoride dentifrice
Number of subjects: 75
Study 21762157 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride control dentifrice
Number of subjects: 75
Study 19689079 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education intervention
Number of subjects: 2556
Study 19689079 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2556
Study 17116767 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 297
Study 14574515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cholecystokinin (CCK-8) infusion at 10 ng/kg over 3 min
Number of subjects: 28
Study 14574515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 28
Study 14574515 — intervention group
Group type: COMPARATOR
Intervention: Opioid group (no intervention specified)
Number of subjects: 28
Study 14574515 — intervention group
Group type: EXPERIMENTAL
Intervention: SOS group (no intervention specified)
Number of subjects: 28
Study 14574515 — intervention group
Group type: EXPERIMENTAL
Intervention: SOS group (after treatment with antispasmodics or endoscopic sphincterotomy)
Number of subjects: 28
Study 14574515 — intervention group
Group type: EXPERIMENTAL
Intervention: SOS group
Number of subjects: 28
Study 14574515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 14574515 — intervention group
Group type: COMPARATOR
Intervention: Opioid group
Number of subjects: 28
Study 11737926 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion (1 unit of packed RBC over 1 h)
Number of subjects: 15
Study 11737926 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin solution (500 ml over 1 h)
Number of subjects: 15
Study 11737926 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 15
Study 11737926 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin solution
Number of subjects: 15
Study 11737926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 15
Study 9613407 — intervention group
Group type: EXPERIMENTAL
Intervention: Written warnings
Number of subjects: 269
Study 9613407 — intervention group
Group type: COMPARATOR
Intervention: Verbal warnings
Number of subjects: 269
Study 8221707 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 30 mg of nicardipine
Number of subjects: 11
Study 8221707 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with nicardipine (60 mg/day for 1 month)
Number of subjects: 11
Study 3120764 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1 1 min before induction of anaesthesia
Number of subjects: 0
Study 3120764 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard technique of general anaesthesia without alfentanil)
Number of subjects: 0
Study 31358721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual piroxicam 40 mg 1 hour prior to surgery
Number of subjects: 40
Study 31358721 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 hour prior to surgery
Number of subjects: 40
Study 30152808 — intervention group
Group type: COMPARATOR
Intervention: RMsham (sham roller massage)
Number of subjects: 16
Study 30152808 — intervention group
Group type: EXPERIMENTAL
Intervention: RMmod (moderate roller massage)
Number of subjects: 16
Study 30152808 — intervention group
Group type: EXPERIMENTAL
Intervention: RMhigh (high roller massage)
Number of subjects: 16
Study 30152808 — intervention group
Group type: EXPERIMENTAL
Intervention: All RM conditions (RMsham, RMmod, RMhigh)
Number of subjects: 16
Study 26319616 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Beginnings, Better Futures (BBBF) initiative
Number of subjects: 626
Study 25286986 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (ATII) infusion at a starting dose of 20 ng/kg/min, titrated to maintain MAP of 65 mmHg for 6 hours
Number of subjects: 20
Study 25286986 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 20
Study 25286986 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (ATII) infusion
Number of subjects: 20
Study 22405707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (persuasive material about canine health from walking and a calendar to mark walks)
Number of subjects: 58
Study 22405707 — intervention group
Group type: COMPARATOR
Intervention: Standard control condition
Number of subjects: 58
Study 21165231 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification
Number of subjects: 85
Study 21165231 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal phacoemulsification
Number of subjects: 85
Study 17671394 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily
Number of subjects: 2775
Study 17671394 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2775
Study 15682368 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated SPECT
Number of subjects: 20
Study 15682368 — intervention group
Group type: COMPARATOR
Intervention: RNA
Number of subjects: 20
Study 11919305 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 309
Study 11919305 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin therapy
Number of subjects: 309
Study 9949315 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 879